Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Correction: Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.

Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, Rotter V.

Oncotarget. 2019 May 7;10(34):3203-3206. doi: 10.18632/oncotarget.26921. eCollection 2019 May 7.

2.

Retraction: Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function.

Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V.

Cancer Res. 2019 Apr 15;79(8):2085. doi: 10.1158/0008-5472.CAN-19-0560. No abstract available.

PMID:
30987981
3.

Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy.

Lonetto G, Koifman G, Silberman A, Attery A, Solomon H, Levin-Zaidman S, Goldfinger N, Porat Z, Erez A, Rotter V.

Cell Death Differ. 2019 Sep;26(9):1566-1581. doi: 10.1038/s41418-018-0227-z. Epub 2018 Nov 9.

4.

A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.

Koifman G, Shetzer Y, Eizenberger S, Solomon H, Rotkopf R, Molchadsky A, Lonetto G, Goldfinger N, Rotter V.

Cancer Res. 2018 Oct 15;78(20):5833-5847. doi: 10.1158/0008-5472.CAN-18-0805. Epub 2018 Aug 28.

5.

Various stress stimuli rewire the profile of liver secretome in a p53-dependent manner.

Charni-Natan M, Solomon H, Molchadsky A, Jacob-Berger A, Goldfinger N, Rotter V.

Cell Death Dis. 2018 May 29;9(6):647. doi: 10.1038/s41419-018-0697-4.

6.

Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.

Solomon H, Dinowitz N, Pateras IS, Cooks T, Shetzer Y, Molchadsky A, Charni M, Rabani S, Koifman G, Tarcic O, Porat Z, Kogan-Sakin I, Goldfinger N, Oren M, Harris CC, Gorgoulis VG, Rotter V.

Oncogene. 2018 Mar;37(12):1669-1684. doi: 10.1038/s41388-017-0060-8. Epub 2018 Jan 18.

7.

Post-translational regulation of p53 function through 20S proteasome-mediated cleavage.

Solomon H, Bräuning B, Fainer I, Ben-Nissan G, Rabani S, Goldfinger N, Moscovitz O, Shakked Z, Rotter V, Sharon M.

Cell Death Differ. 2017 Dec;24(12):2187-2198. doi: 10.1038/cdd.2017.139. Epub 2017 Sep 8.

8.

Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.

Shetzer Y, Napchan Y, Kaufman T, Molchadsky A, Tal P, Goldfinger N, Rotter V.

Int J Cancer. 2017 Mar 15;140(6):1364-1369. doi: 10.1002/ijc.30554.

9.

Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.

Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, Rotter V.

Oncotarget. 2016 Mar 15;7(11):11817-37. doi: 10.18632/oncotarget.7857.

10.

Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation.

Charni M, Molchadsky A, Goldstein I, Solomon H, Tal P, Goldfinger N, Yang P, Porat Z, Lozano G, Rotter V.

Cell Death Differ. 2016 Mar;23(3):509-20. doi: 10.1038/cdd.2015.119. Epub 2015 Sep 11.

11.

The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.

Shetzer Y, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M, Kaufman T, Zapatka M, Molchadsky A, Rivlin N, Dinowitz N, Levin S, Landan G, Goldstein I, Goldfinger N, Pe'er D, Radlwimmer B, Lichter P, Rotter V, Aloni-Grinstein R.

Cell Death Differ. 2014 Sep;21(9):1419-31. doi: 10.1038/cdd.2014.57. Epub 2014 May 16.

12.

Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.

Rivlin N, Katz S, Doody M, Sheffer M, Horesh S, Molchadsky A, Koifman G, Shetzer Y, Goldfinger N, Rotter V, Geiger T.

Proc Natl Acad Sci U S A. 2014 May 13;111(19):7006-11. doi: 10.1073/pnas.1320428111. Epub 2014 Apr 28.

13.

p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production.

Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E, Rotter V.

Cancer Metab. 2013 Feb 4;1(1):9. doi: 10.1186/2049-3002-1-9.

14.

Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta.

Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V.

PLoS One. 2013 Apr 22;8(4):e61353. doi: 10.1371/journal.pone.0061353. Print 2013.

15.

p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity.

Molchadsky A, Ezra O, Amendola PG, Krantz D, Kogan-Sakin I, Buganim Y, Rivlin N, Goldfinger N, Folgiero V, Falcioni R, Sarig R, Rotter V.

Cell Death Differ. 2013 May;20(5):774-83. doi: 10.1038/cdd.2013.9. Epub 2013 Feb 15.

16.

Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues.

Landan G, Cohen NM, Mukamel Z, Bar A, Molchadsky A, Brosh R, Horn-Saban S, Zalcenstein DA, Goldfinger N, Zundelevich A, Gal-Yam EN, Rotter V, Tanay A.

Nat Genet. 2012 Nov;44(11):1207-14. doi: 10.1038/ng.2442. Epub 2012 Oct 14.

PMID:
23064413
17.

Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53.

Goldstein I, Rivlin N, Shoshana OY, Ezra O, Madar S, Goldfinger N, Rotter V.

Carcinogenesis. 2013 Jan;34(1):190-8. doi: 10.1093/carcin/bgs318. Epub 2012 Oct 10.

PMID:
23054612
18.

p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition.

Brosh R, Assia-Alroy Y, Molchadsky A, Bornstein C, Dekel E, Madar S, Shetzer Y, Rivlin N, Goldfinger N, Sarig R, Rotter V.

Cell Death Differ. 2013 Feb;20(2):312-20. doi: 10.1038/cdd.2012.125. Epub 2012 Sep 21.

19.

Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.

Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buganim Y, Stambolsky P, Goldstein I, Madar S, Rotter V.

J Cell Sci. 2012 Nov 15;125(Pt 22):5578-86. doi: 10.1242/jcs.106815. Epub 2012 Aug 16.

20.

Apoptotic-like programed cell death in fungi: the benefits in filamentous species.

Shlezinger N, Goldfinger N, Sharon A.

Front Oncol. 2012 Aug 7;2:97. doi: 10.3389/fonc.2012.00097. eCollection 2012.

21.

Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature.

Solomon H, Buganim Y, Kogan-Sakin I, Pomeraniec L, Assia Y, Madar S, Goldstein I, Brosh R, Kalo E, Beatus T, Goldfinger N, Rotter V.

J Cell Sci. 2012 Jul 1;125(Pt 13):3144-52. doi: 10.1242/jcs.099663. Epub 2012 Mar 16.

22.

p53, a novel regulator of lipid metabolism pathways.

Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, Rotter V.

J Hepatol. 2012 Mar;56(3):656-62. doi: 10.1016/j.jhep.2011.08.022. Epub 2011 Oct 26.

PMID:
22037227
23.

Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression.

Buganim Y, Madar S, Rais Y, Pomeraniec L, Harel E, Solomon H, Kalo E, Goldstein I, Brosh R, Haimov O, Avivi C, Polak-Charcon S, Goldfinger N, Barshack I, Rotter V.

Carcinogenesis. 2011 Dec;32(12):1749-57. doi: 10.1093/carcin/bgr203. Epub 2011 Sep 7.

PMID:
21900211
24.

TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model.

Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R.

PLoS One. 2011;6(7):e21650. doi: 10.1371/journal.pone.0021650. Epub 2011 Jul 1.

25.

SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63.

Bornstein C, Brosh R, Molchadsky A, Madar S, Kogan-Sakin I, Goldstein I, Chakravarti D, Flores ER, Goldfinger N, Sarig R, Rotter V.

Mol Cell Biol. 2011 Apr;31(8):1679-89. doi: 10.1128/MCB.01072-10. Epub 2011 Feb 7.

26.

Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer.

Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R, Ke XS, Oyan AM, Kalland KH, Rotter V, Domany E.

PLoS One. 2011 Jan 31;6(1):e14632. doi: 10.1371/journal.pone.0014632.

27.

Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.

Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, Molchadsky A, Goldfinger N, Brenner O, Rotter V.

J Exp Med. 2010 Sep 27;207(10):2127-40. doi: 10.1084/jem.20100797. Epub 2010 Aug 9.

28.

Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.

Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, Barshack I, Brait M, Sidransky D, Domany E, Rotter V.

Cell Death Differ. 2011 Feb;18(2):271-81. doi: 10.1038/cdd.2010.94. Epub 2010 Aug 6.

29.

p53-dependent transcriptional regulation of EDA2R and its involvement in chemotherapy-induced hair loss.

Brosh R, Sarig R, Natan EB, Molchadsky A, Madar S, Bornstein C, Buganim Y, Shapira T, Goldfinger N, Paus R, Rotter V.

FEBS Lett. 2010 Jun 3;584(11):2473-7. doi: 10.1016/j.febslet.2010.04.058. Epub 2010 Apr 29.

30.

A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype.

Buganim Y, Goldstein I, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, Solomon H, Kalo E, Madar S, Brosh R, Perelman M, Navon R, Goldfinger N, Barshack I, Yakhini Z, Rotter V.

PLoS One. 2010 Mar 11;5(3):e9657. doi: 10.1371/journal.pone.0009657.

31.

p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.

Buganim Y, Solomon H, Rais Y, Kistner D, Nachmany I, Brait M, Madar S, Goldstein I, Kalo E, Adam N, Gordin M, Rivlin N, Kogan I, Brosh R, Sefadia-Elad G, Goldfinger N, Sidransky D, Kloog Y, Rotter V.

Cancer Res. 2010 Mar 15;70(6):2274-84. doi: 10.1158/0008-5472.CAN-09-2661. Epub 2010 Mar 2.

32.

Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer.

Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N, Rotter V.

Mol Cancer Res. 2009 Aug;7(8):1212-23. doi: 10.1158/1541-7786.MCR-09-0073. Epub 2009 Aug 11.

33.

Identification of gene networks associated with erythroid differentiation.

Peller S, Tabach Y, Rotschild M, Garach-Joshua O, Cohen Y, Goldfinger N, Rotter V.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):74-80. doi: 10.1016/j.bcmd.2009.01.020. Epub 2009 Mar 28.

PMID:
19329339
34.

Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.

Ke XS, Qu Y, Rostad K, Li WC, Lin B, Halvorsen OJ, Haukaas SA, Jonassen I, Petersen K, Goldfinger N, Rotter V, Akslen LA, Oyan AM, Kalland KH.

PLoS One. 2009;4(3):e4687. doi: 10.1371/journal.pone.0004687. Epub 2009 Mar 5.

35.

Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1.

Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, Molchadsky A, Brosh R, Buganim Y, Goldfinger N, Klocker H, Schalken JA, Rotter V.

Carcinogenesis. 2009 Apr;30(4):698-705. doi: 10.1093/carcin/bgp043. Epub 2009 Feb 20.

PMID:
19233959
36.

Cancer cells suppress p53 in adjacent fibroblasts.

Bar J, Feniger-Barish R, Lukashchuk N, Shaham H, Moskovits N, Goldfinger N, Simansky D, Perlman M, Papa M, Yosepovich A, Rechavi G, Rotter V, Oren M.

Oncogene. 2009 Feb 12;28(6):933-6. doi: 10.1038/onc.2008.445. Epub 2008 Dec 8.

37.

p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation.

Brosh R, Shalgi R, Liran A, Landan G, Korotayev K, Nguyen GH, Enerly E, Johnsen H, Buganim Y, Solomon H, Goldstein I, Madar S, Goldfinger N, Børresen-Dale AL, Ginsberg D, Harris CC, Pilpel Y, Oren M, Rotter V.

Mol Syst Biol. 2008;4:229. doi: 10.1038/msb.2008.65. Epub 2008 Nov 25.

38.

p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner.

Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A, Tzahor E, Lozano G, Zipori D, Sarig R, Rotter V.

PLoS One. 2008;3(11):e3707. doi: 10.1371/journal.pone.0003707. Epub 2008 Nov 12.

39.

Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation.

Ke XS, Qu Y, Goldfinger N, Rostad K, Hovland R, Akslen LA, Rotter V, Øyan AM, Kalland KH.

PLoS One. 2008;3(10):e3368. doi: 10.1371/journal.pone.0003368. Epub 2008 Oct 13.

40.

Modulated expression of WFDC1 during carcinogenesis and cellular senescence.

Madar S, Brosh R, Buganim Y, Ezra O, Goldstein I, Solomon H, Kogan I, Goldfinger N, Klocker H, Rotter V.

Carcinogenesis. 2009 Jan;30(1):20-7. doi: 10.1093/carcin/bgn232. Epub 2008 Oct 8.

41.

Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Kalo E, Buganim Y, Shapira KE, Besserglick H, Goldfinger N, Weisz L, Stambolsky P, Henis YI, Rotter V.

Mol Cell Biol. 2007 Dec;27(23):8228-42. Epub 2007 Sep 17.

42.

Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress.

Tang X, Milyavsky M, Goldfinger N, Rotter V.

Oncogene. 2007 Nov 15;26(52):7302-12. Epub 2007 May 28.

PMID:
17533371
43.

Enhanced angiotensin II production by renal mesangium is responsible for apoptosis/proliferation of endothelial and epithelial cells in a model of malignant hypertension.

Efrati S, Berman S, Goldfinger N, Erez N, Averbukh Z, Golik A, Rotter V, Weissgarten J.

J Hypertens. 2007 May;25(5):1041-52.

PMID:
17414669
44.

Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect.

Milyavsky M, Shats I, Cholostoy A, Brosh R, Buganim Y, Weisz L, Kogan I, Cohen M, Shatz M, Madar S, Kalo E, Goldfinger N, Yuan J, Ron S, MacKenzie K, Eden A, Rotter V.

Cancer Cell. 2007 Feb;11(2):133-46.

45.

Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction.

Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I, Kalis M, Goldfinger N, Rotter V.

Cancer Res. 2006 Nov 15;66(22):10750-9.

46.

Regulation of AIF expression by p53.

Stambolsky P, Weisz L, Shats I, Klein Y, Goldfinger N, Oren M, Rotter V.

Cell Death Differ. 2006 Dec;13(12):2140-9. Epub 2006 May 26.

47.

hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis.

Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G, Klocker H, Wasylyk B, Voller M, Aalders T, Schalken JA, Oren M, Rotter V.

Cancer Res. 2006 Apr 1;66(7):3531-40.

48.

Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein.

Orgad S, Goldfinger N, Cohen G, Rotter V, Solomon B.

FEBS Lett. 2005 Oct 24;579(25):5609-15. Epub 2005 Sep 28.

49.

Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation.

Milyavsky M, Tabach Y, Shats I, Erez N, Cohen Y, Tang X, Kalis M, Kogan I, Buganim Y, Goldfinger N, Ginsberg D, Harris CC, Domany E, Rotter V.

Cancer Res. 2005 Jun 1;65(11):4530-43.

50.

Transactivation of the EGR1 gene contributes to mutant p53 gain of function.

Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V.

Cancer Res. 2004 Nov 15;64(22):8318-27. Retraction in: Cancer Res. 2019 Apr 15;79(8):2085.

Supplemental Content

Loading ...
Support Center